Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
about
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipientsPre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humansHIV-1 Vaccine Trials: Evolving Concepts and DesignsAutoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Frequent associations between CTL and T-Helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designsElimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10Cellular immunity survey against urinary tract infection using pVAX/fimH cassette with mammalian and wild type codon usage as a DNA vaccineThe External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assayIL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality.Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine developmentAn HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses.Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation.Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic miceInnovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Enrichment of Ly6C(hi) monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model.Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV-1 polyepitope CTL immunogen.Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization.Revisiting GM-CSF as an adjuvant for therapeutic vaccines.Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant
P2860
Q24602593-EF735D57-9673-44A6-9184-427CAC6FB0C4Q28741103-1CEB117A-4074-4B94-B417-9170C87ED747Q30425520-01A68920-D731-4EFB-B4A9-153E019EB76EQ33601372-24D46488-E2FA-41AD-B94F-C53AFFEE7BF7Q33652911-292D6576-3D37-437E-AFC7-B1AC89C1EA2AQ33699560-7FD08A74-48B2-4CD5-8565-70003A9CC8E7Q33850497-EC430A4B-9FD2-410D-8190-1328540E7DA4Q34066932-72219921-6455-479E-A34E-EB329E30A5B8Q34289072-AF635AAA-E235-4AD2-9D3B-94203FF31B44Q35049812-85C7F58A-25A2-4D67-9C80-8791EC509DBBQ35063075-2F56B08B-292E-46EA-92E7-BB9256AB49EAQ35232804-D45D6702-12B7-4BE4-BEBA-AF00393312BEQ35887235-4D586CDC-1AD7-4008-A3C1-4F0B0E8A6219Q36162133-216635A0-389C-46B8-801F-619F11830EDDQ36625724-4E03356B-FBB7-4EB9-BD42-4E6FA1A21837Q36766857-A1E0D363-0F7C-4D18-9A2A-14C6B768E89EQ36795668-529EE155-E062-4C98-B496-2C2974F24BE8Q37402451-76C68403-8672-4BA4-AAF9-F8BA9D7F779EQ37748492-A574601E-DDC6-47A6-8C62-5A1F33DBE291Q38059499-44692F4C-7960-45FE-9DFA-A045B85F660FQ40126197-666099EC-01F2-4827-9B98-0843336BED25Q41834074-152DA5AB-9E41-4698-99ED-B9AA419F1DF8Q44569389-0360F324-C897-4089-A42C-C3FE2431C552Q47604194-6C848F22-4304-49AB-9FEC-C5719AF60CDFQ57824837-0D196728-6543-4578-8E90-586E6B081C38
P2860
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Safety and immunogenicity of a ...... out GM-CSF in a phase I trial.
@en
Safety and immunogenicity of a ...... out GM-CSF in a phase I trial.
@nl
type
label
Safety and immunogenicity of a ...... out GM-CSF in a phase I trial.
@en
Safety and immunogenicity of a ...... out GM-CSF in a phase I trial.
@nl
prefLabel
Safety and immunogenicity of a ...... out GM-CSF in a phase I trial.
@en
Safety and immunogenicity of a ...... out GM-CSF in a phase I trial.
@nl
P2093
P2860
P50
P1433
P1476
Safety and immunogenicity of a ...... out GM-CSF in a phase I trial.
@en
P2093
Barbara Metch
John H Eldridge
Jonathan D Fuchs
Kent J Weinhold
Marnie Elizaga
Michael C Keefer
Michael D Lubeck
Michael Egan
NIAID HIV Vaccine Trials Network
Paul Spearman
P2860
P304
P356
10.1016/J.VACCINE.2008.10.051
P407
P577
2008-11-07T00:00:00Z